
ISB
Research
The Institute of Structural Biology is interested in the structure-function relationship of biological macromolecules. Our work combines protein biochemistry, biophysics, X-ray crystallography, cryo electron microscopy, and molecular biology to understand biological phenomena at atomic resolution.
Regulation of transcription
The transcription cycle is regulated by cyclin-dependent kinases that phosphorylate RNA polymerase II and general transcription factors. We analyse how the transition from transcription initiation to productive elongation, polyadenylation, and termination is mediated in eukaryotic cells.
After transcription initiation, RNA polymerase II pauses approximately 50-150 nucleotides downstream of the transcription start site. Release from this block requires the positive transcription elongation factor P-TEFb, a heterodimer composed of the cyclin-dependent kinase Cdk9 and the regulatory subunit Cyclin T. Cdk9 mediates the transition from transcription initiation to productive elongation of pre-mRNA transcripts by phosphorylation of the C-terminal domain of RNA polymerase II. Other cyclin-dependent kinases, including Cdk7, CDK8, Cdk11, Cdk12, and Cdk13, contribute to transcriptional initiation, pre-mRNA processing, and splicing regulation.
We aim to understand the molecular and structural mechanisms that determine the activity and regulation of transcription-cycle controlling kinases. Malfunction of gene expression at the transcriptional level contributes to multiple diseases, including cancer, leukaemia, HIV infection, and myocardial hypertrophy.
Selected reading:
- Düster, R., et al. (2024). Structural basis of Cdk7 activation by dual T-loop phosphorylation. Nature Communications 15:6597.
- Insco, M.L., et al. (2023). Oncogenic CDK13 mutations impede nuclear RNA surveillance. Science 380:eabn7625.
- Düster, R., et al. (2022). Functional characterization of the human Cdk10/Cyclin Q complex. Open Biology 12:210381.
- Kaltheuner, I.H., et al. (2021). Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nature Communications 12:6607.
- Eick, D. and Geyer, M. (2013). The RNA polymerase II carboxy-terminal domain code. Chemical Reviews 113, 8456-8490.
Inflammation
The immune system permanently defends the human body against a wide range of pathogens. A common response to harmful stimuli is inflammation. The cytosolic receptor protein NLRP3 is a member of the Nod-like receptor family and recognizes pathogen-associated and danger-associated molecular patterns in immune cells. These signals activate NLRP3 and lead to formation of a high-molecular assembly called the inflammasome.
NLRP3 is a multi-domain protein of 120 kDa that is expressed in myeloid cells such as macrophages. We analyse the structure of NLRP3 as well as other Nod-like receptors and correlate structural features with the function and activity of these inflammatory receptors. A broad range of molecular, biochemical, and structural techniques is applied to study the effects of activation and nucleotide binding in NLRs.
Connecting structure and function in NLRP3 provides insight into the molecular assembly of the inflammasome and identifies key sites for regulation and targeted inhibition of this immune receptor.
Selected reading:
- Feng, S., et al. (2025). Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants. Nature Immunology 26, 511-523.
- Cosson, C., et al. (2024). Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation. Journal of Experimental Medicine 221:e20231200.
- Kopp, A., et al. (2023). Pyroptosis inhibiting nanobodies block Gasdermin D pore formation. Nature Communications 14:7923.
- Brinkschulte, R., et al. (2022). ATP-binding and hydrolysis of human NLRP3. Communications Biology 5:1176.
- Hochheiser, I.V., et al. (2022). Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604, 184-189.
Protein Design
Protein design connects structural insight with engineering. We use atomic-resolution models, biochemical validation, and biophysical assays to understand and shape protein interactions, binders, and molecular tools for mechanistic studies.
Recent advances in AI-based structure prediction and generative modelling make it possible to design small proteins with defined folds and tailored binding properties. In our work, we combine computational design with experimental screening to identify artificial protein binders and to understand why individual designs succeed or fail. This includes structural filtering, protein production, binding assays, cell-surface display, and biochemical optimization.
One focus is the development of small, robust minibinders against medically relevant target proteins. These molecules can serve as research tools and may provide starting points for future therapeutic strategies. At the same time, protein design offers a powerful way to test basic principles of molecular recognition, stability, specificity, and protein-protein interaction.
Selected reading:
- Broske, B., et al. (2026). AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature Communications 17:8736. doi: 10.1038/s41467-026-76760-5.
Bacterial immunity
Bacterial immunity relies on specialized defence systems that detect and respond to infection. We are particularly interested in type III CRISPR systems, which recognize foreign RNA and convert this signal into the production of cyclic nucleotide second messengers.
These signalling molecules activate downstream effector proteins that can shut down infection by targeting essential cellular processes. We study how these antiviral pathways are organized at the molecular level, how cyclic nucleotides switch effector proteins on, and how CRISPR-associated enzymes communicate with cellular machineries such as proteases and transcription factors.
Combining structural biology, biochemistry, and biophysics allows us to follow bacterial immune signalling from nucleic acid recognition to effector activation. This work provides insight into the diversity of microbial defence systems and reveals molecular principles that may be useful for future biotechnology.
Selected reading:
- Rouillon, C., Schneberger, N., Chi, H., Blumenstock, K., Da Vela, S., Ackermann, K., Moecking, J., Peter, M.F., Boenigk, W., Seifert, R., Bode, B.E., Schmid-Burgk, J.-L., Svergun, D., Geyer, M., White, M.F. and Hagelueken, G. (2023). Antiviral signaling by a cyclic nucleotide activated CRISPR protease. Nature 614, 168-174. doi: 10.1038/s41586-022-05571-7.
- Binder, S.C., Schneberger, N., Schmitz, M., Engeser, M., Geyer, M., Rouillon, C. and Hagelueken, G. (2024). The SAVED domain of the type III CRISPR protease CalpL is a ring nuclease. Nucleic Acids Research gkae676. doi: 10.1093/nar/gkae676.
Membrane transporters
Every living cell is surrounded by at least one lipid bilayer. This thin membrane is about 4 nm thick and enables the cell to establish a carefully balanced composition of nucleic acids, proteins, cofactors, nutrients, and ions. At the same time, traffic of molecules and information across this barrier must be controlled. This task is performed by membrane proteins. In humans, roughly 25% of all protein-coding genes encode membrane proteins, many of which are important drug targets.
Among the processes controlled by membrane proteins is the decoration of bacterial lipopolysaccharides with sialic acid. Bacterial lipopolysaccharides are highly diverse carbohydrate structures and strong activators of the human innate immune system. Some pathogens, including Vibrio cholerae and Haemophilus influenzae, attach sialic acid molecules to their lipopolysaccharides as a strategy to avoid or dampen the innate immune response.
These pathogens use tripartite ATP-independent periplasmic transporters to scavenge sialic acid from host tissues. TRAP transporters are not present in humans and are therefore interesting both from a biochemical perspective and as potential drug targets. They consist of three subunits, commonly called P, Q, and M. The P domain collects the substrate in the periplasm and shuttles it to the transporter subunits Q and M. We employ X-ray crystallography and cryo-EM in combination with biophysical techniques to determine the structure and function of TRAP transporter domains.
Selected reading:
- Vinothkumar, K.R. and Henderson, R. (2010). Structures of membrane proteins. Quarterly Reviews of Biophysics 43, 65-158.
- Raetz, C. and Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71, 635-700.
- Rabus, R., Jack, D.L., Kelly, D.J., and Saier, M.H. (1999). TRAP transporters: an ancient family of extracytoplasmic solute-receptor-dependent secondary active transporters. Microbiology 145, 3431-3445.
- Mulligan, C., Fischer, M., and Thomas, G.H. (2011). Tripartite ATP-independent periplasmic transporters in bacteria and archaea. FEMS Microbiology Reviews 35, 68-86.
Software
The institute also maintains and uses specialist analysis tools, including the mtsslSuite project for spin-labeling and distance-restraint workflows.